Form 4: Baxter SVP Zielinski Granted 30,864 RSUs

Baxter International's SVP, CAO, and Controller, Anita A. Zielinski, was granted 30,864 restricted stock units.

Summary

• Anita A. Zielinski, Senior Vice President, Chief Accounting Officer, and Controller of Baxter International Inc. (BAX), acquired 30,864 shares of common stock.
• The acquisition occurred on February 27, 2026, and was a grant of restricted stock units (RSUs) with a price of $0 per share.
• These RSUs are scheduled to vest in three equal annual installments, beginning on March 1, 2027.
• Vesting is subject to the requirements outlined in the Amended and Restated Baxter International Inc. 2021 Incentive Plan.
• Following this transaction, Ms. Zielinski beneficially owns a total of 48,214 shares of common stock.
• The total beneficial ownership includes shares from the automatic reinvestment of dividends.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting standard executive compensation practices that align management incentives with shareholder interests, without indicating any immediate operational or financial changes.

Positives

• The grant of 30,864 restricted stock units aligns executive incentives with long-term shareholder value.
• Increased beneficial ownership by a key executive demonstrates confidence in the company's future.

Future Outlook

The restricted stock units granted to Anita A. Zielinski are scheduled to vest in three equal annual installments, commencing on March 1, 2027, contingent upon the satisfaction of vesting requirements under the company's 2021 Incentive Plan.

Industry Context

StockSavvy.ai notes that the grant of restricted stock units to a senior executive like a Chief Accounting Officer is a standard practice in the industry for executive compensation. This mechanism is widely used across publicly traded companies to incentivize long-term performance and align management interests with those of shareholders, similar to practices seen at peers like Medtronic or Abbott Laboratories.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) as a component of executive compensation is a common practice among large-cap healthcare companies, aligning with industry standards for long-term incentive plans.
• The vesting schedule of three equal annual installments is typical for RSU grants, comparable to programs at companies such as Johnson & Johnson or Danaher Corporation, which aim to retain key talent and foster sustained performance over several years.

Corporate Governance

Stakeholder Impact

• Shareholders: The RSU grant aligns the interests of a key executive with long-term shareholder value through equity ownership and performance-based vesting.
• Employees: Reflects the company's compensation strategy for senior leadership, potentially influencing broader compensation philosophies.

Next Steps

• The restricted stock units will begin vesting in three equal annual installments starting March 1, 2027, subject to the terms of the 2021 Incentive Plan.

Key Dates

Keywords

Baxter International, BAX, Restricted Stock Units, RSU Grant, Executive Compensation, Insider Transaction, Form 4, Equity Award